Over the last few years, understanding of the molecular pathology of ovarian cancer has been advanced both by looking for loss of heterozygosity (LOH) that may be revealed by utilising restriction fragment length polymorphisms (RFLPs), recognised by DNA probes, and by studies of amplification and/or rearrangement of candidate oncogenes. We have used these techniques to study both LOH and amplification on the long arm of chromosome 11 in epithelial ovarian cancer (EOC) .
Molecular abnormalities of chromosome 11 have been reported in EOC, but most studies have concentrated on LOH involving known genes such as HRAS and insulin, both mapping to lplS.5 (Lee et al., 1989; Ehlen & Dubeau, 1990; Lee et al., 1990; Sato et al., 1991; Viel et al., 1991) . In contrast, chromosome lq has not received much attention in EOC. Three LOH studies (Lee et al., 1990; Li et al., 1991; Sato et al., 1991) in EOC have used a probe derived from FGF3, (previously INT2), which maps to (Ragoussis et al., 1992) , and is amplified in a limited number of mainly epithelial tumours (Lammie & Peters, 1991) . None of the reports have noted amplification, and LOH appears to be a very infrequent event. Sasano et al. (1990) , reported amplification of FGF3 in 1/16 carcinomas from a series of 24 ovarian tumours. They did not study LOH. Recently, Pejovic et al. (1992) reported five cases of a translocation involving 1lq13 and other chromosomes in their series of 35 EOC patients.
The multiple endocrine neoplasia type 1 (MENI) gene maps to 1 1q13 (Larsson et al., 1988; Fujimori et al., 1992) and LOH on 1 lq has been reported in MENl-associated tumours (Friedman et al., 1989; Thakker et al., 1989) . In most cases, all informative probes on 1 lq showed LOH, but given the linkage data, the tumour suppressor gene is likely to be in 1Iq13. Significant LOH on llq has also been reported in cervical cancer (Srivatsan et al., 1991a) and neuroblastoma (Srivatsan et al., 1991b ). Campbell et al. (1991 and Coney et al. (1991) have reported the cloning of the gene that encodes the antigen recognised by MOvI8, a murine monoclonal antibody reactive with over 80% of nonmucinous ovarian adenocarcinomas (Miotti et al., 1987) . This gene is the adult highaffinity folate receptor (FOLRJ) (Ratnam et al., 1989; Elwood, 1989) , which maps to llq13.3-13.5 (Ragoussis et al., 1992) . We noted its proximity to FGF3, to the bcll translocation breakpoint in B cell lymphomas, (Tsujimoto et al., 1985) and to PRAD1, a bcll-linked gene which may be important in 1q13 amplification (Rosenberg et al., 1991) .
Given Futreal et al. (1992) , where they used primers mapping to chromosome 17. Therefore, as well as RFLP DNA probes telomeric to 1 1q13, we used the primers L7.1/2 and Mfd69, both of which map to Iq23.3. By using these probes from 1 1q14-1 lqter, we have extended these findings with LOH data and defined the minimum deleted region.
Materials and methods

Materials
Tumours were collected from consenting patients undergoing surgery for ovarian cancer. Lymphocytes were extracted from blood taken at the time or within a few days of the operation. These patients were unselected and were operated on at a number of hospitals in and around London. Tumour tissue was initially dissected, and then frozen in isopentane before storing the samples in liquid nitrogen. Frozen sections were then taken from representative parts of the tumour and stained with haematoxylin and eosin. The proportion of tumour to stroma was recorded. The frozen sections allowed us to select the most tumour-rich part of the specimen for further analysis. Classification of the ovarian tumours by histopathological grade was carried out according to the WHO classification (Serov et al., 1973, pp. 17-54) , with some modifications (Russell, 1987, pp. 556-622;  Anderson, 1991, pp. 303-344) . This method of classification is reproducible; the criteria include architectural and cytological features as well as the maximum mitotic index, nuclear morphology and the degree of necrosis. using phenol-chloroform in the final stages, we used saltchloroform, according to the method of Miillenbach et al. (1989) . Lymphocyte DNA was also extracted using the saltchloroform method. The histopathological classification and grading of the tumours is shown in Table I . Figure 2 . Absence of amplifcation is marked by a dash (-) . Sample 47 showed LOH with DIISJ47, an RFLP marker, at 1 q23.3-qter (Figure 2 ), but retention at DIIS29 and CD3D, (both at llq23.3) (Figure 3 ). The relative intensity of the alleles in these cases remained constant with both shorter (15) and longer (40) (Table III) , but this trend was not significant. The lack of significance may be due to the small number of tumours studied, with a bias towards advanced tumours. There was also no significant correlation between histological type and LOH on llq.
Discussion
Chromosome 11 q has been studied in many tumours and in particular there has been extensive investigation of 11 q 13 in a large number of solid and haematological tumours (Lammie & Peters, 1991) . The region appears to contain a number of cancer-related genes, and on average, between 5 and 50% of tumours of various types show modest amplification of some or all of this large band. Amplification at 1 1q13 in our study was at a frequency similar to the 1/16 cases reported in EOC by Sasano et al. (1990) which is at the lower end of the range previously reported for other tumours. The copy number is slightly lower than that reported in breast cancer, which is usually 3-10 fold (Lammie & Peters, 1991) . It is likely that the gene(s) around the bc1l breakpoint (Motokura et al., 1991; Rosenberg et al., 1991; Schuuring et al., 1992 ) is driving amplification seen in EOC. FOLRI overexpression in ovarian carcinoma is thought to be the result of increased transcription, but the mechanism by which this occurs has not been elucidated (Campbell et al., 1991) . However, our results have demonstrated that neither amplification nor LOH can explain this elevation and therefore the mechanism is probably not genetic in origin but may relate to local factors such as low levels of folate and subsequent upregulation of expression of the FOLRI gene (Campbell et al., 1991) . (Figure 4) . A number of cytogenetic reports in ovarian tumours have noted the consistent, but infrequent finding of translocations and deletions involving l1q23-q25 (Jenkyn & McCartney, 1987; Pejovic et al., 1989; Bello & Ray, 1990; Pejovic et al., 1992) . Interestingly, a translocation t(I;ll)(q25;q23) was seen as the only karyotypic abnormality in a mucinous cystadenoma (Pejovic et al., 1990) , suggesting that such translocations may be significant early events in the pathogenesis of malignant ovarian neoplasia. How these reports in ovarian tumours relate to the much more commonly seen (and better characterised) 1 1q23 translocations in haematological disorders is unknown at present, but interestingly, data from studies in acute leukaemia and lymphoma (Zieman-van der Poel et al., 1991) suggest that one of the breakpoint regions present on chromosome 11 in a number of different haematological malignancies is approximately 200 kb telomeric to CD3D. The region around CD3D may be important for a number of different malignancies including EOC. Figure 4 demonstrates the LOH seen in three tumours at DIIS144, DIIS29, CD3D and D11S147. The positions of these markers shown in the figure are based on the publications of Foroud et al. (1991); Zieman-van der Poel et al. (1991) and Heutink et al. (1992) .
It is noteworthy that two fragile sites (FRAlIB, rare and folic acid sensitive, and FRAlIG, common and aphidicolin fr.pn sensitive) are present at 1 1q23.3. However, there are no published reports of possible involvement of these two sites in the evolution of any human cancer, nor are they thought to be coincident upon known breakpoints. Support for the fragile site hypothesis of cancer appears generally to be waning (Hecht, 1988) and although it is possible that random chromosomal breakages occur more frequently at fragile sites in the later stages of neoplasia, there are no data to support a causal role.
Our molecular studies suggest that functional deletions of genes on llq23.3-qter may be more common in EOC that is suggested by the cytogenetic data. Very recently Heutink et al. (1992) reported linkage of hereditary paragangliomas in a large Dutch pedigree to DJJS147, a probe used in the present study which is an anonymous DNA marker mapping to 1lq23.3-qter. This finding supports the notion that there is a gene implicated in tumourigenesis adjacent to or telomeric of 1lq23.3 and thus this region appears to be important in a number of different tumours types. An expanded LOH study using recently described polymorphic markers from 1 lq23.3-1 lqter (Tanigami et al., 1992) should lead to a finer mapping of this deletion in ovarian cancer.
The data presented here suggest that LOH and amplification on llq are quite distinct events that involve separate regions of the chromosome. We have shown by LOH studies that the minimal region of LOH on chromosome llq in EOC is llq23.3-qter. The high level of LOH at 1lq23.3-qter in EOC reported here brings the number of chromosomal loci significantly involved (>50% LOH) in these tumours to eight: 3p (Ehlen & Dubeau, 1990) ; 6p (Sato et al., 1991) ; 6q (Ehlen & Dubeau, 1990 ; Lee et al., 1990) ; 1 Ip (Lee et al., 1989; Lee et al., 1990) ; 1 lq (this study); 17p (Lee et al., 1990; Eccles et al., 1990; Tsao et al., 1991) ; 17q (Russell et al., 1990; Eccles et al., 1990; and 18q (Chenevix-Trench et al., 1992) . In our experience, the late stage tumours are likely to show concomitant loss of most of these regions.
